Myricanol
Based on 1 Customer Validation
Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.93%
- CAS. Nr.: 33606-81-4
- Formel: C21H26O5
- Molecular Weight:358.43
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Alle AMPK Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
|
SIRT1 |
NF-κB |
AMPK |
PDGFRβ |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
7.5 μM
Compound: 153
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based spectrophotometrical method
|
[PMID: 33422907] |
In Vitro
Myricanol (0.01-150 μM ,1-72 h) effectively reduces tau levels in HEK293T cells with IC50 of approximately 18.56 μM and mouse acute ex vivo brain tissues (100 and 150 μM) through activation of autophagy[1].
Myricanol (0-10 μM, 24 h) significantly reverses the reduction in mitochondrial content and functional impairment induced by Dexamethasone (DEX) (HY-14648), and promotes autophagy and inhibits apoptosis to protect C2C12 myotubes through activating sirtuin 1[2].
Myricanol (1.25-5 μmol/L, 24 h) decreases lipid accumulation and enhances mitochondrial function in Palmitic acid (PA) (HY-N0830)-treated C2C12 myotubes and protects C2C12 myotubes against insulin resistance, and increases irisin production and secretion in C2C12 myotubes, which in turn induces the browning of adipocytes[3].
Myricanol (5-20 μM) inhibits renal fibrosis by invigorated TFAM and ameliorate the interaction between ZNRF1 and LCN2 and aggravates ferroptosis in TGF-β1-induced HK2 cells[4].
MY (2.5-10 μM) protects C2C12 myotubes against oxidative damage treated by tert-butyl hydroperoxide (TBHP) and improves mitochondrial biogenesis and function through targeting PRDX5[5].
Myricanol (3-30 μM, 24.5 h) inhibits the proliferation and migration of vascular smooth muscle cells induced by platelet derived growth factor-BB by inhibiting the activation of platelet-derived growth factor receptor pathway and NF-κB p65 translocation[6].
Myricanol (5-40 μM, 24 h) targets Nampt in C2C12 cells, which involved in the insulin sensitizing effect[7].
Myricanol (1.56-50 μg/mL, 48 h-10 d) inhibits A549 cells proliferation (IC50 = 4.85 μg/mL) and clonogenic formation and induces apoptosis[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293T cells
-
Concentration:18 μM
-
Incubation Time:1, 6, 24, 48, 72 h
-
Result:Completely be blocked the tau-lowering effect by 3-MA (HY-19312).
Increased the LC3β-II/I ratio.
-
Cell Line:C2C12 myotubes stimulated by with DEX
-
Concentration:0, 0.25, 5, 10 μM
-
Incubation Time:24 h
-
Result:Restored the expression of myosin heavy chain (MyHC), muscle atrophy F-box protein (atrogin-1), and muscle ring-finger protein 1 (MuRF1).
Dose-dependent upregulated SIRT1 expression.
Restored the phosphorylation of Akt and FoxO3a that is inhibited by DEX.
Increased the expression levels of Cox2, Tom20, UCP3, and PGC-1α.
Reversed DEX-induced increases of total and acetylated FoxO3a levels, which were abolished by co-treatment of EX-527 (HY-15452).
Inhibited expression of apoptosis-associated proteins Bax, cleaved caspase-3 and Increased Bcl-2.
-
Cell Line:C2C12 myotubes stimulated by with PA
-
Concentration:1.25, 2.5, and 5 μmol/L
-
Incubation Time:24 h
-
Result:Activated the AMPK/ACC signaling pathway and upregulated the expression of PGC-1α.
Activated of the insulin signaling pathway (IRS-1/Akt/GSK-3β).
Promoted the production and secretion of FNDC5/irisin.
Decreased the lipid accumulation in 3T3‐L1 adipocytes in a dose-dependent manner.
Increased the browning markers, PGC‐1α and UCP1, and the mitochondrial marker, COX2, and Suppressed the adipogenic marker, PPARγ, in 3T3‐L1 adipocytes, dose-dependently.
-
Cell Line:Primary VSMCs
-
Concentration:3, 10 and 30 μM
-
Incubation Time:Pretreated 30 min and treated with PDGF-BB for 24 h
-
Result:Partially suppressed the migration at 10 and 30 μM.
-
Cell Line:Primary VSMCs
-
Concentration:3, 10 and 30 μM
-
Incubation Time:Pretreated 30 min and treated with PDGF-BB for 24 h
-
Result:Reduced PCNA, E2F1 and p-Rb.
Reduced Cyclin D1, Cyclin E1 and recovered p53.
Inhibited MM2 and MM9.
Inhibited PDGFRβ pathway and MAPK pathway.
Significantly inhibited p65 nuclear accumulation.
-
Cell Line:A549 cells
-
Concentration:1.56, 3.125, 6.25, 12.5, 25 and 50 μg/mL
-
Incubation Time:48 h
-
Result:Inhibited cell proliferation in a concentration-dependent manner.
-
Cell Line:A549 cells
-
Concentration:5 μg/mL
-
Incubation Time:48 h
-
Result:Increased the apoptosis rate from 4.13% to 34.3%, and the proportion of early apoptosis increased significantly.
Upregulated Caspase-3, Caspase-9, Bax and p21, downregulated Bcl-2.
In Vivo
Myricanol (0.5-2.5 mg/mL, dissolved in PEG 400 (HY-Y0873A) solution, i.p., once daily for 18 weeks) retards fat mass gain and improves lipid profiles and improves insulin sensitivity in high-fat diet (HFD)-fed mice[3].
Myricanol (0.5-2 mg/mL, i.p., once daily for 1 weeks) efficiently improves renal function and suppresses fibrosis in chronic kidney disease (CKD) mice[4].
Myricanol (10-50 mg/kg, i.p., once daily for 20 days) protects aged mice against muscle wasting through alleviating oxidative damage in mitochondria and identify the direct protein target and its underlying mechanism[5].
Myricanol (5 mg/kg, i.p., once daily for 14 days) significantly diminishes the neointimal hyperplasia induced by carotid artery ligation[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DEX-induced muscle dysfunction established in male C57BL/6 mice (8-10 weeks old)[2]
-
Dosage:5 and 50 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 10 days
-
Result:Reduced the loss of muscle mass.
Rescued dexamethasone-induced muscle weakness, indicated by improved grip strength.
Upregulated SIRT1 and PGC-1α, reduced atrogin-1/MuRF1.
-
Animal Model:HFD model established in male C57BL/6 mice (8-10 weeks old)[3]
-
Dosage:0.5 and 2.5 mg/mL, dissolved in PEG 400 (HY-Y0873A) solution
-
Administration:Intraperitoneal injection (i.p.), once daily for 18 weeks
-
Result:Inhibited weight gain induced by high-fat diet and reduces fat tissue accumulation.
Improved the glucose tolerance and insulin sensitivity of HFD mice (reduce the HOMA-IR index).
Reduced serum triglycerides, total cholesterol and LDL cholesterol, and increased HDL cholesterol).
Increased energy consumption (oxygen consumption).
Reduced lipid deposition in skeletal muscles and improved muscle function (as measured by grip strength test).
Activated the AMPK/PGC-1α signaling pathway in skeletal muscle.
Increased the expression of FNDC5 in skeletal muscle and the serum level of irisin.
Induced the browning of white adipose tissue in the groin region.
-
Animal Model:CKD model induced by unilateral ureteral obstruction (UUO) established in male C57BL/6 mice (6-8 weeks old)[4]
-
Dosage:0.5 and 2 mg/mL along with an equal volume of normal saline
-
Administration:Intraperitoneal injection (i.p.), once daily for one weeks
-
Result:Significantly reduced serum creatinine and urea nitrogen levels.
Showed a 40-60% reduction in collagen deposition.
Downregulated fibrosis markers (FN, α-SMA).
Significantly upregulated TFAM and GPX4 expressions and decreased 4-HNE.
-
Animal Model:Sarcopenia phenotypes model established in 18-month-old male C57BL/6J mice[5]
-
Dosage:10 and 50 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 10 days
-
Result:Improved grip strength in aging mice.
Significantly improved Quad, Gast and TA muscle index.
Reduced mitochondrial vacuolization and cristae structure disruption.
-
Animal Model:Carotid artery wire ligation injury model established in eight-week-old male C57BL/6 mice[6]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 14 days
-
Result:Showed significantly reduced intima, both the ratio of intima to media (I/M ratio) and intimal area.
Had significantly inhibited Ki67 expression and F4/80 expression.
Chemical Information
-
CAS. Nr. 33606-81-4
-
Appearance Solid
-
Molecular Weight 358.43
-
Formel C21H26O5
-
Color White to off-white
-
SMILES
COC1=C(C=C(CCCC[C@H]2O)C(O)=C1OC)C(C=C(CC2)C=C3)=C3O
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Nuclear Protein Extraction (High-Salt/Hypotonic Fractionation)
The high-salt/hypotonic fractionation method for nuclear protein extraction is based on the differential solubility of cellular components. Cytoplasmic proteins are extracted first using a hypotonic buffer that causes cell swelling and membrane rupture, followed by centrifugation to separate the cytoplasmic supernatant from the nuclear pellet. The nuclear pellet is then subjected to high-salt extraction (e. g. , 0. 4 M (NH4)2SO4 or 1 M NaCl) to solubilize tightly bound nuclear matrix proteins, including transcription factors, histones, and structural proteins associated with chromatin and the nuclear scaffold. This approach allows for the isolation of both soluble cytoplasmic proteins and salt-resistant nuclear proteins while minimizing cross-contamination.
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Reinheit & Dokumentation
-
Data Sheet (297 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Martin MD, et al. Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance. ACS Chem Biol. 2015;10(4):1099-1109. [Content Brief]
[2]. Shen S, et al. Myricanol rescues dexamethasone-induced muscle dysfunction via a sirtuin 1-dependent mechanism. J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):429-444. [Content Brief]
[3]. Shen S, et al. Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance. Br J Pharmacol. 2019 Oct;176(20):3983-4001. [Content Brief]
[4]. Zheng M, et al. Myricanol represses renal fibrosis by activating TFAM and ZNRF1 to inhibit tubular epithelial cells ferroptosis. Eur J Pharmacol. 2024 Dec 5;984:176999. [Content Brief]
[5]. Shen S, et al. Myricanol prevents aging-related sarcopenia by rescuing mitochondrial dysfunction via targeting peroxiredoxin 5. MedComm (2020). 2024 Jun 12;5(6):e566. [Content Brief]
[6]. Fan S, et al. Myricanol Inhibits Platelet Derived Growth Factor-BB-Induced Vascular Smooth Muscle Cells Proliferation and Migration in vitro and Intimal Hyperplasia in vivo by Targeting the Platelet-Derived Growth Factor Receptor-β and NF-κB Signaling. Front Physiol. 2022 Feb 3;12:790345. [Content Brief]
[7]. Lyu P, et al. Affinity-based protein profiling-driven discovery of myricanol as a Nampt activator. Bioorg Chem. 2023 Apr;133:106435. [Content Brief]
[8]. Dai GH, et al. Growth-inhibiting and apoptosis-inducing activities of Myricanol from the bark of Myrica rubra in human lung adenocarcinoma A549 cells. Phytomedicine. 2014 Sep 25;21(11):1490-6. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)